Project Grant R01AR088081
Award Date 8/18/26
Completion Date 7/31/31
Dollars Obligated $504K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Waco, TX 76798, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Cincinnati Children's Hospital Medical Center $510,175 on August 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the molecular mechanisms of skeletal muscle cell fusion. The research integrates biochemical, cellular, and genetic strategies to define the lipid pathways that enable myomaker-dependent lipid remodeling in myoblasts and establish the...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Baylor College of Medicine $679,931 on April 20, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The project investigates how SPEG kinase regulates calcium leak from the sarcoplasmic reticulum via phosphorylation of the RYR1 calcium release channel at serine 2902, with direct application to understanding and treating congenital myopathies and malignant hyperthermia...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the University of Missouri System $350,561 on July 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The Project Grant (R21AR086497) funds research into syndecan-4's role in regulating satellite cell activity through dynamic multiprotein complexes. The research examines how syndecan-4 mediates myogenic progression—the transition of satellite cells from...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Duke University $377,506 on June 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop a chimeric antigen receptor T cell (CAR-T) therapy targeting inflammation and fibrosis in Duchenne muscular dystrophy. The research will evaluate CAR-T cells engineered to eliminate pro-inflammatory macrophages and fibrogenic fibro-adipogenic progenitors in the dystrophic muscle...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Baylor College of Medicine $374,000 on August 17, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the role of the transcription factor TONEBP/NFAT5 in regulating chondrocyte energy availability and extracellular matrix synthesis during postnatal bone growth. The research examines how chondrocytes balance intense matrix production with protein quality...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $401,625 to the University of California, Los Angeles on March 15, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to support a mechanistic ancillary study on skeletal muscle recovery and mitochondrial function in older cancer survivors. The project evaluates the effects of exercise combined with oral senolytic therapy on muscle mass, strength, and mitochondrial...
- The National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Duke University $124,875 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate muscle-to-bone communication during fracture repair and musculoskeletal regeneration. The research identifies pro-regenerative signals from injured muscle that orchestrate repair of both bone and muscle tissue. Preliminary findings...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $151,040 to The University of Texas Southwestern Medical Center on April 15, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop muscle-optimized non-viral gene editors for Duchenne muscular dystrophy. The project addresses limitations in lipid nanoparticle (LNP) delivery of CRISPR gene editing to skeletal muscle by designing gene editors that improve myonuclear...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $614,390 to the University of Georgia Research Foundation on May 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the molecular mechanisms of human myogenesis, specifically the role of the CHAMP1 gene in muscle development and CHAMP1 syndrome. The research focuses on myoblast fusion, an essential process for muscle development and regeneration. Prior...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded The Johns Hopkins University $543,417 on June 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate functional neuromuscular regeneration following chronic volumetric muscle loss in aged mice. The research addresses the restoration of neuromuscular junctions after volumetric muscle loss, a critical-sized skeletal muscle injury in which natural healing...